Autoimmunity After Checkpoint Blockade

This study is tracking cancer patients who receive immunotherapy drugs called checkpoint inhibitors (such as pembrolizumab or nivolumab) to understand how these treatments affect the immune system and whether they trigger autoimmune conditions. Checkpoint inhibitors help the immune system fight cancer, but they can also cause the immune system to attack the body's own healthy tissues. This study is monitoring patients for new or worsening autoimmune conditions that appear after checkpoint inhibitor treatment. You may be eligible if: - You are 18 years or older - You have been diagnosed with cancer - Your doctor has prescribed a checkpoint inhibitor immunotherapy for you You may NOT be eligible if: - You are under 18 years of age - You are unwilling or unable to provide informed consent - You have had an organ transplant Talk to your oncologist if you are about to start or are currently receiving checkpoint inhibitor immunotherapy — monitoring for immune-related side effects is important, and participating in this study may help researchers better manage autoimmune complications in cancer patients.